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CC BY-NC-ND license (http://creativeBackground/purpose: Intravenous immunoglobulin (IVIG) plays a central role in the treatment
of antibody-mediated rejection (AMR) of renal allografts, but the treatment outcomes for late
AMR (>6 months after transplantation) are poor.
Methods: We performed a retrospective study to assess the response patterns of IVIG-based
(2 g/kg) desensitization for late AMR. Patients who received desensitization after the patholog-
ical diagnosis of late AMR positive for complement component C4d were grouped as the Desen-
sitized Group and compared to a historical Control Group with complement component C4d
positivity in retrospective stainings.
Results: The 10-year graft survival of the Desensitized Group (73.9%, nZ 35) was significantly
better than that of the historical Control Group (35.0%, nZ 40) without desensitization. In the
Desensitized Group, a subgroup of patients (D2 Subgroup, n Z 11), who responded to desen-
sitization initially but deteriorated later, was identified to benefit from repeated cycles of
desensitization at 31.1  20.9 months. Patients receiving only one cycle of desensitization
were further grouped into D1-good (n Z 10) and D1-poor (n Z 14) based on their long-term
renal function. The D2 Subgroup patients did not exhibit significant improvements in renal
function compared to the D1-poor patients, until 30 months after IVIG-based desensitization,
suggesting desensitization therapy has a working window of approximately 24 months.ave no conflicts of interest relevant to this article.
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Early antibody-mediated rejection (AMR) of renal trans-
plantation has been successfully treated by desensitization
therapy including plasmapheresis and administration of
intravenous immunoglobulin (IVIG) or rituximab, an anti-
CD20 antibody targeting B cells. Nonetheless, late AMR,
diagnosed 6 months post-transplantation or later, remains a
clinical problem causing graft dysfunction and eventually
failure.1,2
Various therapeutic agents and combination regimens
have been reported to treat AMR of renal transplants. The
combination of plasmapheresis and IVIG was previously
demonstrated to improve outcomes of early AMR,
compared to plasmapheresis alone.3 In addition, IVIG in
combination with rituximab stabilizes the progressive loss
of transplant function in pediatric patients with chronic
AMR.4 However, Gupta et al2 showed that late AMR cases
responded poorly to plasmapheresis, IVIG, and rituximab
therapy, even upon addition of bortezomib, a proteasome
inhibitor used to deplete plasma cells. Rituximab and IVIG
therapy for transplant glomerulopathy during chronic AMR
do not change the natural course of chronic AMR and could
be associated with serious cytopenia and infections.5 No
randomized controlled studies have been conducted to
study the treatment of late AMR do date; possibly because
of heterogeneous patient populations and difficulty in
research funding.6
IVIG plays a central role in desensitization therapy for
AMR, thus, we have adopted a strategy of repeated
desensitization using high-doses of IVIG (total dose: 2 g/kg)
and double filtration plasmapheresis (DFPP) in our trans-
plant center since 2007. In this paper, we present an
analysis of treatment patterns and responses based on our
single-center experience of late AMR treatment with high-
dose IVIG and plasmapheresis.Methods
Patient populations
A retrospective study was performed to assess the outcome
of late AMR among 968 renal transplantation patients,
treated at a single transplant center between January 1990
and December 2012. Renal biopsy results and medical re-
cords were reviewed from the date of transplantation to
June 2015. Complement component C4d (C4d) staining was
conducted in all renal transplant biopsies, including in
those obtained prior to the setup of the C4d staining
method, if the paraffin-embedded specimens were avail-
able in our hospital. The results of C4d staining wereincorporated into the original pathological reports of the
patients as supplements, because positive staining of C4d in
renal transplant biopsies is considered one of the predom-
inant characteristics of AMR and suggestive of poor long-
term graft survival. In the case of positive retrospective
C4d staining, patients were asked to undergo an update
biopsy, if the renal allografts were still functioning. Further
treatment would be instituted according to the update bi-
opsy. If patients were positive for C4d in the retrospective
staining and desensitized according to the update biopsy,
their results were not included. Approval of the research
ethics committee was not mandatory for retrospective data
analysis in this study.
Study groups
Thirty-five patients who received timely desensitization
therapy for late AMR (> 6 months after transplantation)
were grouped as the Desensitized Group. We then identi-
fied a Control Group of 40 patients with C4d-positive (>
50%) staining in their late-event-based biopsy who did not
receive any desensitization therapy. Those who received
rituximab, eculizumab, bortezomib, or any other antibody
therapy were not included in this study. Demographics and
clinical outcomes of the Desensitized and Control Groups
were collected to test the hypothesis that desensitization
of late AMR with IVIG and DFPP improves long-term graft
survival. Furthermore, the Desensitized Group was sub-
grouped according to treatment and response to desensi-
tization. Ten patients who responded well to one course of
desensitization therapy and enjoyed long-term improved
renal function were subgrouped as D1-good. Another 11
patients of the Desensitized Group receiving > 2 cycles of
desensitization therapy were subgrouped as D2. However,
there were 14 patients, subgrouped as D1-poor, who did not
receive repeated cycles of desensitization therapy even
though their renal function deteriorated during follow-up.
Diagnosis of AMR
A renal biopsy was routinely suggested to renal transplant
patients in our transplant center with a serum creatinine
elevation > 30%, significant proteinuria, or persistent
edema. The pathological findings were interpreted by an
experienced renal pathologist. Patients included in this
study were those with graft dysfunction combined with >
50% C4d positivity in the peritubular capillaries and
morphological evidence of tissue injury and microvascular
inflammation.7 Those who had documented glomerulone-
phritis in the pathological reports, such as mem-
branoproliferative or IgA glomerulonephritis, were not
included in this study. Daily urine protein levels and flow
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before desensitization and thereafter on an annual basis.
One Lambda LabScreen Single Antigen tests were used to
confirm the presence of donor-specific antibody (DSA) at
the time of diagnosis of AMR. DSA positivity was defined as
any allogeneic antibody [> 300 mean fluorescence intensity
(MFI)], targeting the unacceptable donor HLAs as assigned
by the single antigen assays.8
Immunosuppressive therapy and desensitization
Immunosuppressive regimens for all patients were based on
a calcineurin inhibitor (CNI), either cyclosporine (CsA) or
tacrolimus (TAC), in combination with mycophenolate
mofetil (MMF) (or mycophenolate sodium) or azathioprine.
The initial target trough levels for TAC and CsA were
8e16 ng/mL and 200e400 ng/mL, respectively, and MMF
was prescribed at an initial dose of 1e2 g/d. White blood
cell counts were maintained at 4000e6000/mm3, unless
intolerance occurred or the maximum dose was reached.
The target blood levels at 12 months were 5e8 ng/mL for
TAC and 100e200 ng/mL for CsA. Corticosteroids were
routinely used after transplantation. The doses of oral
immunosuppressive drugs including CNIs, MMF (or sodium)
and steroid were basically not changed for the reason of
AMR and desensitization.
The desensitization therapy for patients with late AMR
included four sessions of DFPP and IVIG performed every
other day. Patients with combined cellular rejection
received a 3-day methylprednisolone (10 mg/kg/d) pulse
therapy. DFPP was performed using a KM-8800 in a Kuraray
plasmapheresis system incorporating a Plasmacure PS-06
and an Evaflux 4A as the plasma fractionator (Kuraray
Medical, Tokyo, Japan), as previously described.9,10 The
exchange volume was set at 50 mL/kg with 300e500 mL
saline solution as the replacement fluid. IVIG was admin-
istered every other day at a dose of 0.5 g/kg immediately
after every DFPP. Renal function, biochemistry, and coag-
ulation profiles were regularly checked during theTable 1 Patient demographics.
Characteristics Desensitized gro
(n Z 35)
Age at transplantation (y) 41.0  12.1
Gender (male:female) 15:20
Donor type (deceased:living) 17:18
HLA mismatches 3.4  1.4
Delayed graft function 7/35 (20.0%)
Calcineurin inhibitor (Tac:CsA) 21:14
AMR time (mo) 59.5  34.5
MDRD GFR on AMR (mL/min) 34.2  13.9
Previous cellular rejection 6/35 (17.1%)
Combined cellular rejection 15/35 (42.9%)
Number of renal biopsies 2.7  1.4
5/10-y graft survival 94.0%/73.9%
10-y patient survival 96.4.0%
Follow-up (mo) 108.0  38.1
AMR Z antibody-mediated rejection; CsA Z cyclosporine; GFR Z g
Disease; TAC Z tacrolimus.desensitization period. Coagulopathy was corrected by
plasma transfusion.
Statistical analysis
Unpaired two-tailed t tests and Fisher’s exact tests were
performed for normally distributed continuous variables
and categorical variables, respectively. Renal transplant
function was calculated by a four-variable Modification of
Diet in Renal Disease (MDRD) equation.11 Transplant graft
failure was defined as the return to renal replacement
therapy for > 30 days. The serum creatinine levels after
graft failure were estimated at 10 mg/dL, and patients who
died with functional grafts were considered to have graft
failure. The endpoints of this study were renal function and
graft survival. Log-rank tests were performed to examine
the prognostic significance of desensitization therapy,
recipient gender, donor type, delayed function, initial CNI,
previous cellular rejection, and combined cellular rejec-
tion. Cox regression analysis was performed to determine
the prognostic significance of age at transplantation, age
and HLA mismatch, AMR time, and MDRD-based estimated
glomerular filtration rate (eGFR) for AMR. Additionally, for
the Desensitized Group, pathological scoring, DSA levels,
and 24-hour proteinuria at the time of AMR diagnosis were
included in the statistical analyses to identify indicators of
treatment responsiveness. Multivariate regression analysis
was then applied step-by-step to factors with statistical
significance in the univariate analysis to identify the inde-
pendent factors for graft survival.
Results
Patient characteristics
Patient demographics of the Desensitized and Control
Groups are summarized in Table 1. The gender distribution
and mean age at transplantation were similar between theup Control group
(n Z 40)
p
39.8  13.7 0.677
20:20 0.644
29:11 0.056
3.3  1.3 0.887
11/40 (27.5%) 0.589
22:18 0.815
50.4  44.2 0.323
30.4  16.2 0.288
17/40 (42.5%) 0.024
12/40 (30.0%) 0.336
2.8  1.5 0.477
60.0%/35.0% < 0.001
94.4% 0.452
86.6  51.1 0.047
lomerular filtration rate; MDRD Z Modification of Diet in Renal
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donor renal transplants in the Desensitized Group (51.4%,
18/35) than in the Control Group (27.5%, 11/40; pZ 0.056);
possibly because of a different attitude toward the cost and
outcome of renal transplantation. The HLA mismatches,
incidences of delayed function, and initial use of CNIs were
similar between the two groups.
Treatment outcome of patients with late AMR
The Desensitized Group had late AMR at 59.5  34.5 months
after transplantation and the Control Group at
50.4  44.2 months (p > 0.05). The MDRD eGFRs at the time
of late AMR were not significantly different between the
Desensitized (34.2  13.9 mL/min) and the Control
(30.4  16.2 mL/min) Groups. However, the Control Group
had a significantly higher incidence of previous cellular
rejection (42.5%, 17/40) than the Desensitized Group had
(17.1%, 6/35) (p Z 0.024). At the time of late AMR, 42.9%
(15/35) and 30.0% (12/40) of the Desensitized and the
Control Groups, respectively, had combined cellular
rejection. Importantly, the Desensitized Group had good
graft survival of 73.9% at 10 years, which was significantly
better (p < 0.001) than that of the Control Group (35.0%;
Figure 1). The patient survival rates between the two
groups were equivalent, but the follow-up duration of the
Desensitized Group (108.0  38.1 months) was longer than
that of the Control Group (86.6  51.1 months; pZ 0.047);
possibly because of better graft survival in the Desensitized
Group.
Renal function after late AMR
While the eGFRs of the Desensitized and Control Groups
were not significantly different at the time of late AMR, the
eGFR changes of the two groups were markedly different
during the first 6 months after AMR: the average eGFR
improved from 34.19  13.85 mL/min to 37.32  13.19 mL/
min in the Desensitized Group, but dropped fromFigure 1 KaplaneMeier estimates of the cumulative graft
survival rates of patients with late antibody-mediated rejec-
tion receiving desensitization (Desensitized Group) or not
(Control Group). The Desensitized Group exhibited significantly
better graft survival than the Control Group (p < 0.001).30.44  16.17 mL/min to 19.77  15.18 mL/min in the
Control Group. After 6 months of desensitization therapy,
the average eGFRs of the Desensitized Group declined
gradually during follow-up but were still significantly better
than those of the Control Group. Six patients in the
Desensitized Group and 28 in the Control Group had graft
failure, and additionally, one patient in the Desensitized
Group and two in the Control Group died within 48 months
after AMR. The average eGFRs of the Desensitized and
Control Groups were significantly different during follow-up
(p < 0.001). Details of the eGFRs of the Desensitized and
Control Groups are shown in Figure 2.
Demographics of the three desensitized subgroups
The demographics of the three subgroups were not signifi-
cantly different (Table 2). The D1-poor Subgroup included
older patients, more male patients, and patients with more
HLA mismatches. The D2 Subgroup (3.6  1.6) underwent
significantly more renal biopsies than the D1-poor Subgroup
(2.2  1.0; pZ 0.017). The D1-poor Subgroup had a longer
average AMR time after transplantation, lower average
eGFR on AMR, and more 24-hour urinary protein than the
other two subgroups, although these differences were not
statistically significant. All patients of the three subgroups
were highly sensitized (PRA > 50%) to either class I or class
II HLA (Table 2). The average highest DSA level of the D1-
poor Subgroup (10365  5919 MFI) was significantly
(p Z 0.015) higher than that of the D2 Subgroup
(3581  2251 MFI). However, the difference in highest DSA
levels between the D1-good Subgroup (2171  2136 MFI)
and D2 Subgroup was not significant (p Z 0.079). Every
patient receiving desensitization therapy had a renal biopsy
showing strong C4d staining (> 50%). The average per-
centages of the C4d staining among the three subgroups
were comparable, and so were the criteria for interstitialFigure 2 Average MDRD-estimated glomerular filtration rate
(eGFR) of the patients in the Desensitized and Control Groups.
The average eGFRs of the Desensitized and Control Groups
were not significantly different at the time of late antibody-
mediated rejection but were significantly different during
follow-up. * p < 0.001. MDRD Z Modification of Diet in Renal
Disease.












Age at transplantation (y) 39.2  9.0 44.0  12.8 39.1  4.5 0.764 0.311
Gender (male:female) 1:9 6:8 3:8 0.676 0.587
Donor type (D:L) 7:3 7:7 3:8 0.083 0.414
HLA mismatches 2.8  1.7 3.9  1.4 3.4  1.2 0.460 0.273
Delayed graft function 2/10 2/14 3/11 1.000 0.623
CNI (TAC:CsA) 8:2 6:8 7:4 0.635 0.428
AMR time (mo) 54.6  36.2 70.9  30.4 50.8  38.4 0.750 0.135
MDRD GFR on AMR 38.4  17.8 31.6  14.9 33.7  7.1 0.434 0.667
24-h urinary protein (mg) 586  756 2888  2743 1369  1411 0.174 0.091
No. of renal biopsies 2.4  1.7 2.2  1.0 3.6  1.6 0.110 0.017
Follow-up (mo) 103.0  41.4 110.8  43.6 111.7  23.3 0.281 0.791
Serological and pathological factors
PRA class I > 50% 4 (40.0%) 8 (57.1%) 4 (36.4%) 1.000 0.428
PRA class II > 50% 6 (60.0%) 11 (78.6%) 7 (63.6%) 1.000 0.656
Highest DSA titer (MFI) 2171  2136 10365  5919 3581  2251 0.079 0.015
MICA antibody positivity 1 (10.0%) 1 (7.1%) 2 (18.1%) 1.000 0.565
C4d (%) 78.0  12.3 71.6  16.0 72.5  15.3 0.388 0.922
ci score 1.1  0.7 1.4  0.7 1.1  0.5 0.975 0.308
ct score 0.9  0.6 0.7  0.5 0.7  0.7 0.522 1.000
cv score 0.5  0.7 1.4  0.8 0.8  1.1 0.489 0.212
cg score 0.5  0.5 1.1  0.9 0.6  0.5 0.695 0.068
ptc score 1.3  0.8 1.4  0.7 1.7  0.8 0.258 0.240
Previous cellular rejection 3 (30.0%) 1 (7.1%) 2 (18.2%) 0.635 0.565
Combined cellular rejection 4 (40.0%) 6 (42.9%) 5 (45.5%) 1.000 1.000
AMR Z antibody-mediated rejection; C4d Z complement component C4d; cg Z criteria for allograft glomerulonephropathy;
ciZ criteria for interstitial fibrosis; CNIZ calcineurin inhibitor; CsAZ cyclosporine; ctZ criteria for tubular atrophy; cvZ criteria for
vascular fibrous intimal thickening; D Z deceased; DSA Z donor-specific antibody; GFR Z glomerular filtration rate; L Z living;
MDRD Z Modification of Diet in Renal Disease; MFI Z mean fluorescence intensity; MICA Z major histocompatibility complex class I-
related chain A; PRA Z panel-reactive antibody; ptc Z peritubular capillaritis; TAC Z tacrolimus.
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tubular capillaritis (ptc) scores, as defined by the Banff
meeting reports.7,28 The cv and cg scores of the D1-poor
Subgroup were higher than those of the other two sub-
groups, but the differences did not reach statistical sig-
nificance; possibly because of the small number of patients
included in this study. The duration of follow-up was not
significantly different among the three subgroups. All the
renal allografts of the patients in the D1-good and D2
Subgroups survived. In the D1-poor Subgroup, one patient
died of a cerebrovascular accident, and eight had graft
failure during follow-up.
Treatment response after desensitization
When eGFRs were compared, the D1-good Subgroup was
not significantly better than the D2 Subgroup. The D2
Subgroup was also not better than the D1-poor Subgroup
during the initial 18 months after desensitization
(Figure 3). However, the D1-poor Subgroup had signifi-
cantly better eGFRs than the Control Group during the first
24 months, suggesting that desensitization therapy was at
least temporarily effective in treating late AMR. For theD1-poor Subgroup and the Control Group, the differences
in eGFRs leveled out 24 months after IVIG and DFPP
therapy. Interestingly, the eGFRs of the D2 Subgroup were
not significantly lower than those of the D1-good Subgroup
until 24 months after the first desensitization therapy. For
the D2 Subgroup, based on follow-up biopsy and C4d
staining, the second desensitization was performed
31.1  20.9 months (median time: 24 months) after the
first. One patient of the D2 Subgroup received a third
desensitization therapy, 22 months after the second one.
When compared with the D1-poor Subgroup with progres-
sive deterioration of eGFRs, the D2 Subgroup had signifi-
cantly better eGFRs 30 months after initial
desensitization. Our regimen of desensitization including
high-dose IVIG and DFPP seemed to have an average
working window of about 24 months.
Prognostic factors for graft survival in patients with
late AMR
The underlying prognostic factors for the long-term
outcome of renal transplantation with late AMR could
be multifactorial; treatment, patient characteristics,
Figure 3 Average MDRD-estimated glomerular filtration rate
(eGFR) of the patients in the three subgroups of the Desensi-
tized Group and in the Control Group. The D1-poor Subgroup
had significantly better eGFRs than the Control Group during
the first 24 months (q p < 0.05, qq p < 0.01). The average
eGFRs of the D2 subgroup were not significantly lower than
those of the D1-good Subgroup until 24 months after the first
desensitization therapy (DD p < 0.01, DDD p < 0.001). The D2
Subgroup had significantly better eGFRs than the D1-poor
Subgroup 30 months after the initial desensitization. *
p < 0.05. ** p < 0.01. MDRD Z Modification of Diet in Renal
Disease.
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regression analyses revealed that desensitization therapy
(p < 0.001), AMR time (p < 0.001), and MDRD eGFR
(p < 0.001) were independent prognostic factors for
patients with late AMR (Table 3). Desensitization therapy
significantly reduced the risk of graft failure [risk ratio
(RR) 0.2557]. The risk of graft failure was also reduced
in function of the time of AMR (RR 0.9759/mo after
transplantation). Importantly, the better the MDRD
eGFRs of the patients were at the time of late AMR, the
lower the risk of graft failure (RR 0.9411/unit of GFR).
As for patients receiving desensitization therapy, 24-
hour urinary protein was the only statistically signifi-
cant prognostic factor (p Z 0.025; Table 3). The RR for
graft failure after desensitization was 1.0003/mg of
urinary protein.Table 3 Final multivariate Cox’s regression model for graft sur
Cox’s regression Regression coefficient Standard erro
Patients with late AMR
Desensitization 1.3637 0.3847
AMR time 0.0243 0.0051
MDRD GFR on AMR 0.0607 0.0145
Patients with desensitization therapy
24-h urinary protein 0.000347 0.000155
AMR Z antibody-mediated rejection; CL Z confidence limit; GFR Z
Disease.Discussion
IVIG plays a central role in the treatment of AMR of renal
transplants, and we demonstrated that high-dose IVIG and
DFPP could rescue most of the patients with late AMR.
However, we found that there was an average working
window of w24 months for our IVIG-based desensitization
therapy. The patients in the D2 Subgroup in this study
showed a temporary improvement in eGFRs up to
6 months after desensitization, but their renal function
still deteriorated during later follow-up. Fortunately,
repeated cycles of desensitization therapy at
31.1  20.9 months after the first treatment stabilized the
situation of the D2 Subgroup. Further prospective studies
are needed to test for the working windows in different
desensitization regimens. The D1-poor Subgroup was
treated during the earlier stage of desensitization therapy
evaluation, when repetition of desensitization was not
included. When compared to the D2 Subgroup, the timing
of AMR diagnosis in the D1-poor Subgroup could have been
too late (70.9  30.4 months vs. 50.8  38.4 months after
transplantation).
The duration of effect for IVIG has not been studied in
patients with late AMR. As Kuitwaard et al12 showed in
patients with GuillaineBarre´ syndrome, serum IgG con-
centrations increased significantly for at least 4 weeks after
a cumulative IVIG dose of 2 g/kg. A low DIgG after treat-
ment was found to be independently associated with poor
response rates, suggesting a second course of IVIG might be
beneficial. Although the circulatory IgG levels could not
possibly last as long as the average working window we
observed, IVIG could exert its immunomodulatory effect via
multiple mechanisms, including through the binding of Fc-g
receptors, foreign and self-antigens, as well as through
inhibition of circulatory myeloid dendritic cells.13e15
Reduction of the IgG concentration to baseline levels or
persistence of HLA antibodies was not necessarily associ-
ated with recurrent AMR episodes.4
Strategies to treat AMR include antibody removal,
depletion of B cells and/or plasma cells, complement in-
hibition, and pleiotropic immunomodulation by IVIG.16
Blockade of terminal complement by eculizumab, an
anti-C5 antibody, was recently reported to be inadequate
to control AMR.17 Combined therapy with rituximab and
IVIG increased the graft survival rate of patients with
chronic AMR, compared to IVIG alone.18 Although ritux-
imab did not increase the risk of infection when used forvival.
r Risk ratio Lower 95% CL Upper 95% CL p
0.2557 2.1177 0.6097 < 0.001
0.9759 0.0344 0.0142 < 0.001
0.9411 0.0891 0.0322 < 0.001
1.0003 0.000044 0.000650 0.025
glomerular filtration rate; MDRD Z Modification of Diet in Renal
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plantation, Kamar et al19,20 showed that its use after
kidney transplantation was associated with a high risk of
infection and infection-related mortality. Late AMR pa-
tients were found to be less responsive to bortezomib
therapy and to have a significant level of residual DSA
afterwards.21 Repeated cycles of bortezomib were thus
suggested to treat patients with refractory late AMR,
which was consistent with our findings that repeated cy-
cles of desensitization might be necessary and helpful.22
Further studies are required to establish the benefits and
side effects of repeated bortezomib therapy in patients
with late AMR.23,24
Considering the effect of treatment repetition, repeated
cycles of IVIG and plasmapheresis had an important impact
on DSA clearance. Failure to reduce antibody levels, as
Everly et al25 demonstrated, was significantly associated
with renal allograft loss after AMR. Pascual et al26 showed
that a rigorous protocol of plasma exchange would signifi-
cantly reduce DSA and improve renal function, at least in
the short term. However, DSA detection in the Luminex-
based assay can indicate a significant risk of decreased
graft survival, but does not predict the outcome in an in-
dividual patient.27 Patients with DSA do not always expe-
rience clinical AMR, and the renal allografts could absorb
HLA antibody.28,29 The endpoints of our study were thus
renal function and graft survival, instead of DSA levels. We
could not evaluate the effect of our desensitization therapy
in DSA reduction in this retrospective study because Lab-
Screen Single Antigen PRA was not performed after desen-
sitization therapy.
Many factors, including graft function, proteinuria,
pathological scoring, and concurrent cellular rejection,
were identified as indicators of responsiveness to desensi-
tization therapy for AMR.30,31 Renal transplant patients
have a better chance for graft survival when AMR occurs
later and when its diagnosis and treatment start in the
context of better renal function. With regard to treatment
responsiveness, 24-hour urinary protein was identified as
the only risk factor for graft failure at a risk ratio of 1.0003/
mg proteinuria. Actually, the ci score (p Z 0.0635), cv
score (p Z 0.0830), and cg score (p Z 0.0686) were of
borderline significance in our study; statistical significance
would probably be obtained with a larger patient sample
size. Recognition of surrogate markers, including sensiti-
zation to HLA, proteinuria, and deterioration of renal
function, is central to the early diagnosis of AMR and suc-
cessful intervention.
Follow-up renal biopsy, in addition to renal function, is
also an important indicator of treatment response and
prognosis for patients with AMR.30,32 In this retrospective
study, we did not regularly perform repeat renal biopsies
in every patient after AMR; especially not in patients in
the D1-good Subgroup with good recovery or patients in
the D1-poor Subgroup with rapidly deteriorating renal
function. It was difficult to persuade patients with stable
renal function or with failing grafts to undergo renal bi-
opsy. Patients in the D2 Subgroup underwent a signifi-
cantly higher number of biopsies than the patients in the
D1-poor Subgroup. We believe that there could be sus-
tained AMR activity in the D2 Subgroup and even in the D1-
good Subgroup. Further biopsy analysis anddesensitization might be advisable in the long run of post-
transplant follow-up.
In conclusion, for C4d-positive late AMR, repeated cycles
of IVIG-based desensitization could be helpful to stabilize
long-term renal function of patients with sustained AMR.
There is a working window of w24 months for IVIG-based
desensitization therapy.
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